arrow
T

Tianqiang Song

Tianjin Medical University
H指数:28
被引数:8,499

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)
2024-12-310
OA
First-line pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC) in the China subpopulation from the phase III KEYNOTE-966 study

中国亚组中,KEYNOTE-966 III期研究评估的晚期胆道癌(BTC)患者使用一线帕博利珠单抗(pembro)联合吉西他滨和顺铂(gem/cis)的治疗方案。

2024-09-011
PRE
Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study
2024-04-286
OAAI
Effect of different PD-1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma
2023-06-229
PRE
Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study
2023-05-0911
OAAI
Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study
2023-04-267
OAAI
Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma Including FGFR2 fusion or rearrangement: Updated overall survival from an open-label, single-arm, multicenter Phase II study
2023-04-141
PRE
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
2023-04-0598
OAAI